home / stock / chma / chma quote
Last: | $3.76 |
---|---|
Change Percent: | -6.0% |
Open: | $4.08 |
Close: | $3.76 |
High: | $4.1 |
Low: | $3.76 |
Volume: | 8,189,439 |
Last Trade Date Time: | 08/05/2021 04:41:57 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.76 | $4.08 | $3.76 | $4.1 | $3.76 | 8,189,439 | 08-05-2021 |
$4 | $4.01 | $4 | $4.05 | $3.865 | 979,802 | 08-04-2021 |
$4.04 | $4.14 | $4.04 | $4.17 | $4 | 554,390 | 08-03-2021 |
$4.17 | $3.99 | $4.17 | $4.18 | $3.99 | 277,416 | 08-02-2021 |
$4 | $4.14 | $4 | $4.17 | $3.97 | 371,430 | 07-30-2021 |
$4.15 | $4.13 | $4.15 | $4.15 | $4.11 | 357,011 | 07-29-2021 |
$4.13 | $4.13 | $4.13 | $4.23 | $4.12 | 472,941 | 07-28-2021 |
$4.14 | $4.15 | $4.14 | $4.21 | $4.11 | 377,563 | 07-27-2021 |
$4.18 | $4.23 | $4.18 | $4.24 | $4.13 | 331,851 | 07-26-2021 |
$4.24 | $4.3 | $4.24 | $4.3 | $4.205 | 192,927 | 07-23-2021 |
$4.31 | $4.31 | $4.31 | $4.3799 | $4.27 | 171,337 | 07-22-2021 |
$4.33 | $4.3 | $4.33 | $4.39 | $4.3 | 205,250 | 07-21-2021 |
$4.29 | $4.13 | $4.29 | $4.32 | $4.13 | 225,382 | 07-20-2021 |
$4.14 | $4.35 | $4.14 | $4.35 | $4.13 | 1,075,739 | 07-19-2021 |
$4.37 | $4.425 | $4.37 | $4.485 | $4.37 | 248,137 | 07-16-2021 |
$4.45 | $4.465 | $4.45 | $4.519 | $4.42 | 187,512 | 07-15-2021 |
$4.48 | $4.57 | $4.48 | $4.6 | $4.45 | 243,304 | 07-14-2021 |
$4.57 | $4.56 | $4.57 | $4.6503 | $4.55 | 157,485 | 07-13-2021 |
$4.61 | $4.64 | $4.61 | $4.68 | $4.5 | 505,067 | 07-12-2021 |
$4.48 | $4.36 | $4.48 | $4.49 | $4.3 | 631,478 | 07-09-2021 |
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...